<DOC>
	<DOCNO>NCT02510976</DOCNO>
	<brief_summary>Controlled cross-over study prucalopride 2 mg daily placebo gastroparesis ( idiopathic diabetic ) . Patients randomize 4 week treatment first regimen ( double-blind ) , follow 2-week washout 4 week treatment second regimen cross-over .</brief_summary>
	<brief_title>Prucalopride Versus Placebo Gastroparesis</brief_title>
	<detailed_description>To assess influence prucalopride ( Resolor® ) 2mg daily , 30 patient idiopathic 30 patient diabetic gastroparesis undergo two gastric empty breath test concomitant assessment meal-related symptom , conclusion two consecutive , 4-week treatment period prucalopride placebo . The order prucalopride placebo treatment randomise initiation study . Medication patient group , 30 patient idiopathic 30 patient diabetic gastroparesis , randomize separately . Half subject receive placebo first ; half receive prucalopride first . Treatment period separate wash-out period 2 week . All drug potentially affect gastrointestinal motility sensitivity discontinue least two week prior initiation study . Informed consent obtain participant . In order establish gastrointestinal symptom quality-of-life profile cohort , patient complete follow validated self-reported instrument baseline two test visit ( table 1 ) : Patients assessment Gastrointestinal symptom ( PAGISYM ) , Patients assessment Gastrointestinal Quality Life Impact ( PAGIQoL ) Gastrointestinal Global Severity Score , Patient Health Questionnaire ( PHQ-15 ) , Appetite Questionnaire , Hospital Anxiety Depression Scale , Visceral Sensitivity Index , Short Form Nepean Dyspepsia Index ( SF-NDI ) . The PAGI-SYM comprehensive questionnaire upper GI symptom , include gastroparesis questionnaire module : Gastroparesis Cardinal Symptom Index ( GCSI ) , validate ( idiopathic ) gastroparesis.26 Furthermore , entire study duration patient complete daily symptom diary , incorporate separate horizontal 100-mm visual analogue scale ( VAS ) 9 upper abdominal symptom . As prucalopride well-known therapeutic effect chronic constipation , patient also register information stool frequency stool type daily diary ( Bristol Stool Scale ) .</detailed_description>
	<mesh_term>Gastroparesis</mesh_term>
	<criteria>Consecutive patient previously establish diagnosis diabetes functional dyspepsia accord Rome III criterion , delay gastric empty ( t1/2 solid ≥ 109 min ) breath test The presence oesophagitis , gastric atrophy erosive gastroduodenal lesion endoscopy presence lesion small bowel Xray major abdominal surgery underlie psychiatric illness use nonsteroidal antiinflammatory drug , steroid , drug affect gastric motility . Major comorbidities</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2015</verification_date>
</DOC>